3 February 2023
SHARE NOW
ATW
Automation & Digitisation
Cell Therapy
Gene Therapy
Logistics
In this Tech Demo, Title21 describes how its Manufacturing Exertion System (MES), a powerful platform of integrated modules can supports autologous and allogeneic workflows.
Title21 demonstrates the applications of the MES cell manufacturing platform whilst showing how to navigate the integrated system built for ease of customer use.
The platform offers a shortened implementation time, reduced configuration efforts and lower workflow costs, whilst providing out-of-the-box modules for evolving protocols.
This demo has been produced in partnership with Title21.
 |
 |
More like this
Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment
Taysha is discontinuing the development of TSHA-120 in GAN following the Type C meeting feedback from the FDA
21 September 2023
Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux
Oxford Biomedica in Exclusive Talks to Acquire ABL Europe from Institut Mérieux.
20 September 2023
The Cell & Gene Therapy Manufacturing Capacity Map
The only live, interactive manufacturing capacity compendium for the advanced therapies industry.
20 September 2023
